Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 2.0700 |
| Open | 2.1000 |
| Bid | 2.1100 x 600 |
| Ask | 2.1400 x 400 |
| Day's range | 2.0500 - 2.1500 |
| 52-week range | 0.5000 - 3.9300 |
| Volume | |
| Avg. volume | 2,242,695 |
| Market cap | 321.536M |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.
- PR Newswire
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management
- PR Newswire
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates.
